IRIS
FABRAZZO, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.574
NA - Nord America 3.663
AS - Asia 595
SA - Sud America 46
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 2
OC - Oceania 2
Totale 8.886
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.655
IT - Italia 1.345
IE - Irlanda 1.093
UA - Ucraina 577
GB - Regno Unito 440
FR - Francia 275
SE - Svezia 274
DE - Germania 229
CN - Cina 218
SG - Singapore 218
FI - Finlandia 149
TR - Turchia 107
GR - Grecia 96
BR - Brasile 44
PL - Polonia 21
BE - Belgio 20
IN - India 13
RU - Federazione Russa 13
CH - Svizzera 11
HK - Hong Kong 10
KR - Corea 10
ES - Italia 7
IR - Iran 7
NL - Olanda 7
CA - Canada 6
EU - Europa 4
JP - Giappone 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
CO - Colombia 2
EG - Egitto 2
HU - Ungheria 2
LT - Lituania 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
TW - Taiwan 2
AT - Austria 1
AU - Australia 1
IL - Israele 1
IS - Islanda 1
JO - Giordania 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 8.886
Salva come PNG Salva come JPEG
Città #
Dublin 1.076
Jacksonville 877
Chandler 542
Santa Clara 361
Princeton 172
Singapore 137
Roxbury 136
Ann Arbor 96
Medford 91
Cambridge 89
Woodbridge 89
Ashburn 87
Boardman 84
Caserta 72
Wilmington 69
Bremen 68
Rome 66
Beijing 65
Naples 59
Milan 56
San Mateo 49
Nanjing 43
New York 37
Des Moines 33
Seattle 32
Düsseldorf 27
Aversa 25
Norwalk 20
Brussels 19
Mountain View 18
Padova 17
Jinan 16
Napoli 16
Catania 15
Florence 15
Marigliano 15
Houston 13
Radomsko 13
Torino 13
Fisciano 12
Shenyang 12
Bari 11
Perugia 11
Palermo 10
Auburn Hills 9
Bologna 9
Helsinki 9
Hong Kong 9
Nanchang 9
Salerno 9
Como 8
Genova 8
Tianjin 8
Turin 8
Catanzaro 7
Genoa 7
Kunming 7
Los Angeles 7
Parma 7
Cava de' Tirreni 6
Hangzhou 6
Pune 6
Seoul 6
Somma 6
Dalmine 5
Haikou 5
Ningbo 5
Redwood City 5
Rio Saliceto 5
Taizhou 5
Verona 5
Adelfia 4
Bagnoli Irpino 4
Bergamo 4
Bern 4
Cagliari 4
Cassano Magnago 4
Castelvetrano 4
Cedar Knolls 4
Ferrara 4
Gangseo-gu 4
Groningen 4
Istanbul 4
Jesi 4
Lanzhou 4
Moscow 4
Pisa 4
Prato 4
San Sebastiano al Vesuvio 4
Scafati 4
Silver Spring 4
São Paulo 4
Venezia 4
Zhengzhou 4
Abu Dhabi 3
Atella 3
Bertinoro 3
Borgo San Lorenzo 3
Cascina 3
Castelnuovo Rangone 3
Totale 5.080
Salva come PNG Salva come JPEG
Nome #
SINDROME METABOLICA E TRATTAMENTO CON ANTIPSICOTICI: DIFFERENZE IN PAZIENTI CON DIAGNOSI DI SCHIZOFRENIA E DISTURBO BIPOLARE 440
Discrasie ematiche transitorie e persistenti indotte dalla clozapina durante le prime diciotto settimane di trattamento 276
CLOZAPINA E ALTRI ANTIPSICOTICI ATIPICI E TIPICI: INCIDENZA E DECORSO DELLE DISCRASIE EMATICHE DURANTE LE PRIME DICIOTTO SETTIMANE DI TRATTAMENTO 183
Trattamento combinato con clorimipramina ed aripiprazolo nella depressione resistente 141
TRATTAMENTO CON ANTIPSICOTICI E COMPARSA DI SINDROME METABOLICA: UNO STUDIO RETROSPETTIVO IN PAZIENTI SCHIZOFRENICI E BIPOLARI 118
Sindrome metabolica e utilizzo di antipsicotici in pazienti con diagnosi di schizofrenia e disturbo bipolare 90
Cancro della mammella e Alessitimia: Freno o Incentivo alla prevenzione? 90
Brain natriuretic peptide as a biomarker of asymptomatic clozapine-related heart dysfunction: a criterion for a more cautious administration. 90
Magnetic resonance imaging of a transient splenial lesion of the corpus callosum resolved within a week 89
Trattamento con antipsicotici e sindrome metabolica: uno studio retrospettivo in pazienti schizofrenici e bipolari 85
Central and peripheral peptides regulating eating behaviour and energy homeostasis in anorexia nervosa and bulimia nervosa: a literature review 79
La depressione resistente al trattamento farmacologico: incremento dell’effetto antidepressivo della clorimipramina determinato dall’aripiprazolo 78
Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs 78
Discrasie ematiche transitorie e persistenti e trattamento con clozapina nelle prime diciotto settimane di terapia 71
From over- to under-weight: treatment of post-surgical anorexia nervosa in morbid obesity 70
Molecular Psychiatry: regulation of gene function 70
Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. 67
Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment 67
Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa 66
Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias 66
Risposta al trattamento con inibitori del reuptake della serotonina nel disturbo ossessivo-compulsivo ad esordio precoce 64
A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa 64
L’Olanzapina è più rapida dell’Aloperidolo nell’indurre Sindrome Metabolica in pazienti schizofrenici ma non nei bipolari 63
Transient and persistent blood dyscrasias induced by clozapine during the first 18 weeks of treatment 62
Leptin production in Bulimia Nervosa 61
Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine 60
Antipsychotic treatment and metabolic syndrome: a retrospective study in schizophrenic and bipolar patients 60
Brain-derived neurotrophic factor (BDNF) nello spettro del comportamento alimentare 60
Duration of untreated illness and outcome of obsessive-compulsive disorder: A naturalistic follow-up study. 60
Antipsychotic Treatment and Metabolic Syndrome: a Comparison between Schizophrenic and Bipolar Patients. 60
Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa 59
Correlati neurofisiologici della risposta clinica ai neurolettici tipici in pazienti schizofrenici al primo episodio di malattia 59
Il trattamento farmacologico dei sintomi negativi della schizofrenia 59
In rats the reserpine induced increase of brain NGF biosynthesis is mediated by corticosteroids 59
Metabolic Syndrome and Antipsychotic treatment: how about schizophrenia and bipolar disorder? 59
I neurosteroidi ed il recettore periferico delle benzodiazepine 58
Studio longitudianle dei livelli plasmatici del cortisolo e delle catecolamine e della risposta al test al desametazone in pazienti con disordine affettivo bipolare 58
Antipsychotic treatment and metabolic syndrome: a retrospective study in schizophrenic and bipolar patients 57
Aumento dei livelli plasmatici di colesterolo e trigliceridi nella bulimia nervosa 57
Are antipsychotics useful in the treatment of anorexia nervosa? A review of the literature 57
Changes of cholinergic, noradrenergic and serotonergic synaptic transmission indices elicited by Ethylcholine Aziridinium ion (AF64A) infused intraventricularly 56
Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients 55
Steroid regulation of Nerve Growth Factor biosynthesis in the CNS 55
Il monitoraggio plasmatico della clozapina e dei suoi principali metaboliti in pazienti schizofrenici 55
Long-term pharmacological treatment in schizophrenia 54
Livelli plasmatici di TNF alfa in pazienti schizofrenici 54
Sciatic nerves transplanted into the CNS exhibit elevated nerve growth factor (NGF) protein levels 54
Pemphigus and skin disease: A comparison of the incidence of stressful life events and personality disorders 53
Effect of treatment duration on plasma levels of clozapine and n-desmethylclozapine in men and women 53
Altered ghrelin physiology in bulimia nervosa: integration with leptin changes 53
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients 53
Plasma leptin and soluble leptin receptor in patients with eating disorders 52
Il monitoraggio plasmatico della clozapina e dei suoi principali metaboliti in pazienti schizofrenici 52
Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder 51
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder. 51
The role of drug therapies in the treatment of anorexia and bulimia nervosa: a review of the literature 51
La sindrome metabolica e l’utilizzo di antipsicotici: quali differenze in schizofrenia e disturbo bipolare? 51
L'anoressia mentale: aspetti eziopatogenetici clinici e terapeutici 51
Una strategia di trattamento combinato con cloripramina ed aripiprazolo nella depressione resistente 51
L'ansia , la depressione e il movimento nell'anziano 51
Livelli plasmatici degli aminoacidi nei pazienti affetti da schizofrenia cronica. 51
Pheripheral peptides regulating meal initiation and termination in bulimia nervosa 51
Pharmacology of Nerve Growth Factor biosynthesis in rat brain 51
Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment 50
Regulation of nerve growth factor receptor mRNA content by dexamethasone: in vitro and in vivo studies 50
Clozapina ed SSRI: indicazioni cliniche ed interazioni farmacocinetiche 50
Transcriptional regulation of Nerve Growth Factor gene 50
Regulation of Nerve Growth Factor receptor biosynthesis: in vitro and in vivo studies 50
Gli endocannabinoidi nei disturbi del comportamento alimentare: implicazioni fisiopatologiche 50
Neonatal mild stress influences the programming of some adult cerebral biochemical structures 50
Transsynaptic regulation of nerve growth factor gene expression 50
Comorbidity of obsessive-compulsive disorder and schizotypal personality disorder: Clinical response and treatment resistance to pharmacotherapy in a 3-year follow-up naturalistic study 50
Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature 50
Opposite modifications in circulating leptin and solubile leptin receptor across the eating disorder spectrum 49
Peripheral ghrelin and PYY responses to food intake and short-term fasting: implications for eating behaviour and gastrointestinal physiology in bulimia nervosa 49
Clozapine treatment and other atypical and typical antipsychotics: incidence and course of blood dyscrasias during the first eighteen weeks of treatment 49
Induction of Nerve Growth Factor gene expression by Beta-adrenergic receptor activation 49
Duration of untreated illness and outcome of the OCD: a three-year prospective study 49
Response to lithium prophylaxis in schizoaffective psychoses 48
Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure 48
Use of clozapine in a patient with schizophrenia and polidipsia 48
Toward a pharmacology of Nerve Growth Factor (NGF) biosynthesis 48
Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia 47
Effects of sciatic nerve transplants after fimbria-fornix lesion: examination of the role of nerve growth factor 47
Clinical and neurophysiological findings in schizophrenic patients with enlarged and normal ventricles 47
Livelli plasmatici di ghrelina in donne obese e non obese con binge eating disorder, donne obese senza binge eating disorder e pazienti con bulimia nervosa 47
Neuroendocrine findings in obsessive-compulsive disorder: implications for drug treatment 46
LA BULIMIA E I DISTURBI CORRELATI: ASPETTI EZIOPATOGENETICI, CLINICI E TERAPEUTICI 46
Disturbo ossessivo-compulsivo ad esordio precoce: caratteristiche cliniche e risposta al trattamento 46
Peripheral peptides in patients with bulimia nervosa and bing eating disorder 46
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study. 46
Safety and Tolerability of Mood Stabilisers 46
Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge eating disorder: relationships to comorbid depression, psychopathology and hormonal variables 44
Correlazione tra risposta clicnica e livelli plasmatici di clozapina e principali metaboliti in un trial standardizzato 44
Time courses of clozapine response and clozapine plasma levels: a one-year prospective study in drug resistant schizophrenic patients 44
Olanzapine is faster than Haloperidol in inducing Metabolic Syndrome in schizophrenics but not in bipolar patients 44
Long-term treatment with clozapine does not affect morning circulating levels of allopregnanolone and THDOC in patients with schizophrenia: a preliminary study 43
Immunoendocrine findings in patients with eating disorders 43
Stimulation of nerve growth factor biosynthesis in developing rat brain by reserpine: steroids as potential mediators 43
Transient and persistent blood dyscrasias induced by clozapine treatment 43
Totale 6.468
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.669
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.669
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020674 0 0 0 0 158 30 189 67 77 77 57 19
2020/20211.412 111 9 173 117 227 23 176 153 18 197 146 62
2021/20221.198 70 7 21 38 435 20 25 44 53 61 90 334
2022/20232.183 187 59 48 160 259 182 4 124 1.042 17 54 47
2023/2024991 80 27 81 76 287 58 35 60 14 26 84 163
2024/2025603 22 36 49 76 420 0 0 0 0 0 0 0
Totale 9.051